The observed variations in circulating GAS5 levels across different studies may arise from differences in study design, including heterogeneity in patient populations (such as various subtypes of cardiovascular disease and the presence of comorbidities like diabetes), sample types (plasma vs. serum), insufficient standardization of detection methods, and the inherently complex dynamic regulation of lncRNA release into circulation [58]. This evidence concerns the gene GAS5 and cardiovascular disorder.